Jounce Therapeutics (NASDAQ:JNCE)‘s stock had its “hold” rating restated by investment analysts at Cowen in a report released on Tuesday, AnalystRatings.com reports.
Several other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 29th. JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Sunday, August 11th. Finally, Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Saturday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Jounce Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.75.
Shares of JNCE traded up $0.25 during mid-day trading on Tuesday, reaching $4.95. The company had a trading volume of 46,356 shares, compared to its average volume of 114,013. The stock has a market cap of $134.91 million, a price-to-earnings ratio of -5.89 and a beta of 3.51. The firm has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $4.26. Jounce Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $7.35. The company has a current ratio of 13.60, a quick ratio of 13.60 and a debt-to-equity ratio of 0.09.
Several large investors have recently bought and sold shares of JNCE. Meeder Asset Management Inc. lifted its holdings in shares of Jounce Therapeutics by 249.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock valued at $25,000 after acquiring an additional 3,594 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Jounce Therapeutics by 595.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 16,073 shares of the company’s stock valued at $54,000 after acquiring an additional 13,763 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Jounce Therapeutics during the 2nd quarter valued at $59,000. Bailard Inc. lifted its holdings in shares of Jounce Therapeutics by 54.1% during the 2nd quarter. Bailard Inc. now owns 22,800 shares of the company’s stock valued at $113,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Jounce Therapeutics during the 3rd quarter valued at $113,000. Institutional investors and hedge funds own 72.55% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Read More: What are catch-up contributions?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.